Baxter(US:BAX) Globenewswire·2025-11-06 21:25Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to these issues [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter's Novum LVP product suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths linked to these defects, yet their remedial measures were deemed inadequate [2]. Group 2: Implications for Baxter - Due to the ongoing issues with the Novum LVP, there is a heightened risk that customers may be instructed to take these devices out of service, potentially halting all new sales [2]. - Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs have been characterized as materially false and misleading [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4].